The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for PU-AD (icapamespib), an epichaperome inhibitor for recurrent malignant glioma developed by privately held biopharmaceutical company Samus Therapeutics.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,